MARAbio's Innovative Blood Test for Autism Detection
MARAbio Systems, Inc. is revolutionizing the field of prenatal health with an innovative blood test designed to diagnose Maternal Autoantibody Related Autism (MARA). In a significant move, the company has successfully secured $19 million in a Series A funding round led by MAK Capital One, LLC. This funding is set to support the commercial launch of their groundbreaking autism diagnostic test, which is anticipated to make its public debut in 2025.
Understanding Maternal Autoantibody Related Autism
MARA represents a distinct biological subtype of autism attributed to specific autoantibodies present in the mother. This discovery is pivotal, as it enables earlier and pre-symptomatic detection of autism in children, which could lead to improved outcomes by allowing timely behavioral interventions. Studies indicate that MARA could be responsible for approximately 20% of autism cases, often manifesting in more profound developmental challenges. With the ability to detect MARA, MARAbio paves the way for proactive measures to support both children and their families.
The Significance of the Investment
The funds garnered from this recent investment round will not only aid in bringing the MARAbio test to market but will also propel the development of therapeutic interventions aimed at treating the effects of the maternal autoantibodies. Vincent A. Forlenza, Chairman of MARAbio's Board of Directors, emphasized how crucial this funding is for accelerating their mission to mitigate the impacts of MARA. The collaboration with MAK Capital signifies a strong endorsement of MARAbio's potential to transform autism diagnostics.
MARAbio's Technology and Mission
Founded with an engineered focus on precision immunology, MARAbio holds exclusive rights to revolutionary discoveries made by Dr. Judy Van de Water at UC Davis. These discoveries underline the biological basis of MARA and led to the development of a proprietary blood test that accurately identifies if women are carriers of the associated antibodies. The test serves a dual purpose: to diagnose children at birth and predict the risk of MARA before pregnancy.
Future Directions of MARAbio's Research
This pioneering test not only aims to identify the risk of MARA but also seeks to empower families and healthcare providers by facilitating early detection methods. The funding will also enable MARAbio to advance its precision immunology platform further, enhancing their ability to develop therapeutic strategies that target the underlying causes of MARA. Michael S. Paul, Ph.D., the CEO of MARAbio, is enthusiastic about the potential impact of their research on family health outcomes.
About MARAbio Systems, Inc.
MARAbio is dedicated to addressing the challenges associated with Maternal Autoantibody Related Autism (MARA). With a mission to detect, treat, and prevent this subtype of autism, the company strives to empower families and provide vital resources to manage autism's impact. Their first product, a simple blood test, redefines the approach to autism diagnostics by allowing for prediction even before clinical symptoms appear.
Frequently Asked Questions
What is Maternal Autoantibody Related Autism?
Maternal Autoantibody Related Autism is a subtype of autism linked to specific autoantibodies in the mother that can impact the development of the child.
How does the blood test work?
The test analyzes maternal blood to detect the presence of antibodies associated with MARA, allowing for early diagnosis and intervention.
Why is early detection important?
Early detection of MARA can lead to timely behavioral interventions, potentially improving the outcomes for children diagnosed with autism.
What will the funding support besides the blood test?
The funding will also support the development of therapeutic interventions aimed at neutralizing the antibodies that cause MARA.
When can we expect the test to be available?
MARAbio aims to launch their autism diagnostic test in 2025, backed by their recent Series A funding.
